The Geneva Biotech Center (GBC) operates with selected partners to develop promising and innovative molecules. The GBC is composed of a lean team of business and scientific experts, each with more than twenty years of experience in biotech.
Products, services, technology
GBC-A1: A phase 1b/2 molecule with a dual mode of action against atrial fibrillation, combined with a superior safety and tolerability profile.
GBC-R1: This new molecule harnesses the natural protection of our gut microbiota against allergic diseases and avoids the downsides of living bacteria.
We collaborate with inventors of innovative drug candidates in indications with a high unmet medical need. We partner with private or institutional investors for the financing of these pre-clinical and clinical projects and with biotech or pharmaceutical companies for co-development of these assets.